Across TCGA pan-cancer cohorts, RNU6-1266P Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RNU6-1266P data layer compared with 18 for mass-spec protein.
The strongest signal is observed in thymoma (THYM), where higher RNU6-1266P Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RNU6-1266P expression acts as an unfavorable survival marker.
THYM, HNSC, and SKCM are the cancer types where RNU6-1266P Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.